Orforglipron is a novel type 2 diabetes and weight loss treatment drug under development and is expected to become an oral alternative to injectable drugs. It belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist family and is similar to the commonly used Wegovy (Semaglutide) and Mounjaro (Tirzepatide). It has the functions of regulating blood sugar, suppressing appetite and enhancing satiety, thereby helping to control weight and blood sugar levels.
Unlike most GLP-1 drugs, the unique advantage of Orforglipron lies in its daily oral tablet form rather than weekly or daily injection administration. This administration method has significantly enhanced patients’ compliance and convenience of use, representing an important advancement for those who dislike injections or have a resistant attitude towards injections.
In clinical trials, Orforglipron demonstrated excellent weight loss effects. Data shows that participants who took Orforglipron daily for 26 consecutive weeks experienced an average weight loss of 8% to 12%, indicating its significant efficacy in weight control. These results have made Orforglipron a new hope for the future treatment of type 2 diabetes and obesity, and also indicate an important trend in the field of GLP-1 drugs, which is shifting from injectable to oral dosage forms.
Post time: Jul-07-2025